https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
Median duration of therapy was 2.7 years (IQR 1.6-4.5) with 95% on statins at last evaluation. There were significant decreases in total cholesterol, LDL-C, and non-high-density lipoprotein cholesterol (non-HDL-C) from baseline to 6 ± 3 months ( 0.001) and from 6 ±3 months to last follow-up ( 0.001). Triglycerides and HDL-C were unchanged but the triglyceride to HDL-C ratio decreased significantly by late follow-up. At final evaluation, median LDL-C had decreased to 3.4 mmol/L (IQR2.8-4.2). No patient had statins d
Like
Comment
Share
